KruppLCharvetL. Two-armed active comparator trials are unethical in paediatric multiple sclerosis – Yes. Mult Scler2020; 26(12): 1470–1472.
2.
GeraldesR. Two-armed active comparator trials are unethical in pediatric multiple sclerosis – No. Mult Scler2020; 26(12): 1472–1473.
3.
Langer-GouldAZhangJLChungJ, et al. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology2011; 77: 1143–1148.
4.
WaubantEBanwellBWassmerE, et al. Clinical trials of disease-modifying agents in pediatric MS: opportunities, challenges, and recommendations from the IPMSSG. Neurology2019; 92(22): e2538–e2549.
5.
ChitnisTArnoldDLBanwellB, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis2018; 379(11): 1017–1027.
6.
KryskoKMGravesJSRenselM, et al. Real-world effectiveness of initial disease-modifying therapies in pediatric Multiple Sclerosis. Ann Neurol. Epub ahead of print 8Apr2020. DOI: 10.1002/ana.25737.
